Deep Brain Stimulation for Early-Stage Parkinson's Disease: An Illustrative Case (original) (raw)

Abstract

Objectives-Subthalamic nucleus (STN) deep brain stimulation (DBS) is an effective intervention in advanced Parkinson's Disease (PD), but its efficacy and safety in early PD are unknown. Our team is conducting a randomized pilot trial investigating DBS in early PD. This report describes one participant who received bilateral STN-DBS.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (29)

  1. Shagam JY. Unlocking the secrets of Parkinson disease. Radiol Technol. 2008; 79:227-30. [PubMed: 18203877]
  2. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004; 291:358-64. [PubMed: 14734599]
  3. Hermanowicz N. Drug therapy for Parkinson's disease. Semin Neurol. 2007; 27:97-105. [PubMed: 17390254]
  4. Wallace BA, Ashkan K, Heise CE, Foote KD, Torres N, Mitrofanis J, et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP- treated monkeys. Brain. 2007; 130:2129-45. [PubMed: 17584773]
  5. Temel Y, Visser-Vandewalle V, Kaplan S, Kozan R, Daemen MA, Blokland A, et al. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res. 2006; 1120:100-5. [PubMed: 16999940]
  6. Spieles-Engemann AL, Behbehani MM, Collier TJ, Wohlgenant SL, Steece-Collier K, Paumier K, et al. Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis. 2010; 39:105-115. [PubMed: 20307668]
  7. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009; 301:63-73. [PubMed: 19126811]
  8. Schupbach WM, Maltete D, Houeto JL, du Montcel ST, Mallet L, Welter ML, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology. 2007; 68:267-71. [PubMed: 17151341]
  9. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006; 355:896-908. [PubMed: 16943402]
  10. Charles PD, Padaliya BB, Newman WJ, Gill CE, Covington CD, Fang JY, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord. 2004; 10:475-9. [PubMed: 15542007]
  11. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000; 23:75-81. [PubMed: 10803796]
  12. Konrad PE, Neimat JS, Yu H, Kao CC, Remple MS, D'Haese PF, Dawant BM. Customized, miniature rapid-prototype stereotactic frames for use in deep brain stimulator surgery: initial clinical methodology and experience from 263 patients from 2002 to 2008. Stereotact Funct Neurosurg. 2011; 89:34-41. [PubMed: 21160241]
  13. Benazzouz A, Breit S, Koudsie A, Pollak P, Krack P, Benabid AL. Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease. Mov Disord. 2002; 17 3:S145-149. [PubMed: 11948769]
  14. Starr PA, Christine CW, Theodosopoulos PV, Lindsey N, Byrd D, Mosley A, Marks WJ. Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations. J Neurosurg. 2002; 97:370-387. [PubMed: 12186466]
  15. Fitzpatrick JM, Konrad PE, Nickele C, Cetinkaya E, Kao C. Accuracy of customized miniature stereotactic platforms. Stereotact Funct Neurosurg. 2005; 83:25-31. [PubMed: 15821366]
  16. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003; 54(3):403-14. [PubMed: 12953276]
  17. Steigerwald F, Potter M, Herzog J, Pinsker M, Kopper F, Mehdorn H, et al. Neuronal activity of the human subthalamic nucleus in the parkinsonian and nonparkinsonian state. J Neurophysiol. 2008; 100:2515-2524. [PubMed: 18701754]
  18. Rodriguez-Oroz MC, Rodriguez M, Guridi J, Mewes K, Chockkman V, Vitek J, DeLong MR, Obeso JA. The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain. 2001; 124:1777-1790. [PubMed: 11522580]
  19. Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. Ann Neurol. 1996; 40:99-107. [PubMed: 8687199]
  20. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1993; 328:176-83. [PubMed: 8417384]
  21. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol. 1999; 56:334-7. [PubMed: 10190824]
  22. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004; 351:2498-508. [PubMed: 15590952]
  23. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6- month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002; 105:245-55. [PubMed: 11939936]
  24. Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology. 1995; 45:1691-6. [PubMed: 7675228]
  25. Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004; 75:834-9. [PubMed: 15145995]
  26. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66:968-977. [PubMed: 16606907]
  27. Espay AJ, Li JY, Johnston L, Chen R, Lang AE. Mirror movements in parkinsonism -evaluation of a new clinical sign. J Neurol Neurosurg Psychiatry. 2005; 76:1355-1359. [PubMed: 16170075]
  28. LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007; 30:256-65. [PubMed: 17909303]
  29. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology. 2002; 58:396-401. [PubMed: 11839838]